NCT00165451View on ClinicalTrials.gov

A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2001

Primary Completion Date

October 31, 2006

Study Completion Date

October 31, 2006

Conditions
Neoplasms
Interventions
DRUG

Thalidomide

Oral administration once daily at night starting at 3mg/Kg for 6 months.

DRUG

Celecoxib

Oral administration twice daily starting at 100mg/dose for 6 months.

DRUG

Etoposide

Oral administration once daily at night starting at 50mg/m2 3 weeks on and 3 weeks off for 6 months.

DRUG

Cyclophosphamide

Oral administration once daily at night starting at 3.5mg/m2 3 weeks on and 3 weeks off for 6 months.

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER

NCT00165451 - A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer | Biotech Hunter | Biotech Hunter